Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs

Table 4 Percentages of specific targets lysis by HLA-A2⁺ effec-tor CTLs induced by PBMCs from chronic hepatitis B patients with different peptide antigens (mean ± SD, n = 27)

E/T ratios	Percentage of specific cell lysis (%)
	Peptide1d	Peptide2d	Peptide3db	Irrelevant controla	Negative controls
12.5	18.7 ± 3.6	23.1 ± 4.9	30.2 ± 6.1	5.1 ± 0.8	4.3 ± 0.6
25	22.7 ± 4.1	28.6 ± 5.6	38.4 ± 7.4	4.5 ± 0.7	7.1 ± 1.0
50	31.3 ± 6.0	33.9 ± 6.5	52.7 ± 10.3	7.3 ± 1.1	7.7 ± 1.3
100	35.5 ± 5.7	39.1 ± 7.3	58.5 ± 15.9	9.5 ± 1.7	8.5 ± 1.5

^aP > 0.05 vs negative control,

^bP < 0.01 vs peptide1 and 2 groups,

^dP < 0.01 vs negative control.